85 related articles for article (PubMed ID: 9817269)
1. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593.
Mehta MP; Tannehill SP; Adak S; Martin L; Petereit DG; Wagner H; Fowler JF; Johnson D
J Clin Oncol; 1998 Nov; 16(11):3518-23. PubMed ID: 9817269
[TBL] [Abstract][Full Text] [Related]
2. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
[TBL] [Abstract][Full Text] [Related]
3. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
4. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
[TBL] [Abstract][Full Text] [Related]
5. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial.
Fu XL; Jiang GL; Wang LJ; Qian H; Fu S; Yie M; Kong FM; Zhao S; He SQ; Liu TF
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):545-52. PubMed ID: 9336130
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC).
Ishikura S; Ohe Y; Nihei K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Nishiwaki Y; Ogino T
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1117-22. PubMed ID: 15752891
[TBL] [Abstract][Full Text] [Related]
7. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
9. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329
[TBL] [Abstract][Full Text] [Related]
10. An accelerated radiotherapy scheme using a concomitant boost technique for the treatment of unresectable stage III non-small cell lung cancer.
Izmirli M; Yaman F; Buyukpolat MY; Yoney A; Unsal M
Jpn J Clin Oncol; 2005 May; 35(5):239-44. PubMed ID: 15886271
[TBL] [Abstract][Full Text] [Related]
11. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.
Maguire PD; Marks LB; Sibley GS; Herndon JE; Clough RW; Light KL; Hernando ML; Antoine PA; Anscher MS
J Clin Oncol; 2001 Feb; 19(3):705-11. PubMed ID: 11157021
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
13. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: long-term results of a phase I/II clinical trial.
Chen M; Chen YY; Bao Y; Xian CG; Liu GZ; Zhang L; Xu GC; Deng XW; Lu TX; Qian JY; Cui NJ
Clin Lung Cancer; 2005 Mar; 6(5):304-9. PubMed ID: 15845182
[TBL] [Abstract][Full Text] [Related]
15. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of human recombinant interferon gamma and accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage IIIA/B nonsmall cell lung cancer.
Shaw EG; Deming RL; Creagan ET; Nair S; Su JQ; Levitt R; Steen PD; Wiesenfeld M; Mailliard JA
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):827-31. PubMed ID: 7860395
[TBL] [Abstract][Full Text] [Related]
18. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer.
De Ruysscher D; Wanders R; van Haren E; Hochstenbag M; Geraedts W; Pitz C; Simons J; Boersma L; Verschueren T; Minken A; Bentzen SM; Lambin P
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):132-8. PubMed ID: 18037581
[TBL] [Abstract][Full Text] [Related]
19. Hyperfractionated accelerated radiotherapy (HART) for inoperable, nonmetastatic non-small cell lung carcinoma of the lung (NSCLC): results of a phase II study for patients ineligible for combination radiochemotherapy.
Koutaïssoff S; Wellmann D; Coucke P; Ozsahin M; Pampallona S; Mirimanoff RO
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1151-6. PubMed ID: 10613307
[TBL] [Abstract][Full Text] [Related]
20. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]